126 related articles for article (PubMed ID: 9243276)
21. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome.
Sulzbacher I; Birner P; Trieb K; Mühlbauer M; Lang S; Chott A
Am J Surg Pathol; 2001 Dec; 25(12):1520-7. PubMed ID: 11717542
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
23. Chondrocytic cell differentiation in clear cell chondrosarcoma.
Aigner T; Dertinger S; Belke J; Kirchner T
Hum Pathol; 1996 Dec; 27(12):1301-5. PubMed ID: 8958302
[TBL] [Abstract][Full Text] [Related]
24. Progression and recapitulation of the chondrocyte differentiation program: cartilage matrix protein is a marker for cartilage maturation.
Chen Q; Johnson DM; Haudenschild DR; Goetinck PF
Dev Biol; 1995 Nov; 172(1):293-306. PubMed ID: 7589809
[TBL] [Abstract][Full Text] [Related]
25. Hypertrophic chondrocytes. The terminal stage of differentiation in the chondrogenic cell lineage?
Pacifici M; Golden EB; Oshima O; Shapiro IM; Leboy PS; Adams SL
Ann N Y Acad Sci; 1990; 599():45-57. PubMed ID: 2221676
[TBL] [Abstract][Full Text] [Related]
26. Cell biology and matrix biochemistry of chondromyxoid fibroma.
Söder S; Inwards C; Müller S; Kirchner T; Aigner T
Am J Clin Pathol; 2001 Aug; 116(2):271-7. PubMed ID: 11488075
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
Kouvaras E; Christoni Z; Siasios I; Malizos K; Koukoulis GK; Ioannou M
Biotech Histochem; 2019 May; 94(4):283-289. PubMed ID: 30605014
[TBL] [Abstract][Full Text] [Related]
28. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
29. NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia.
Yu C; Le AT; Yeger H; Perbal B; Alman BA
J Pathol; 2003 Dec; 201(4):609-15. PubMed ID: 14648665
[TBL] [Abstract][Full Text] [Related]
30. Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas.
Dornauer K; Söder S; Inwards CY; Bovee JV; Aigner T
Pathol Int; 2010 May; 60(5):365-72. PubMed ID: 20518886
[TBL] [Abstract][Full Text] [Related]
31. The clinical pathological significance of Thy1 and CD49f expression in chondrosarcomas.
He L; Yang Z; Li Z
Pathol Res Pract; 2016 Jul; 212(7):636-42. PubMed ID: 27155928
[TBL] [Abstract][Full Text] [Related]
32. Responses to altered oxygen tension are distinct between human stem cells of high and low chondrogenic capacity.
Anderson DE; Markway BD; Bond D; McCarthy HE; Johnstone B
Stem Cell Res Ther; 2016 Oct; 7(1):154. PubMed ID: 27765063
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic features of osteochondroma with malignant transformation].
Zheng L; Zhang HZ; Huang J; Tang J; Liu L; Jiang ZM
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):609-13. PubMed ID: 20079189
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
35. TGF-β signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells.
Shinohara N; Maeda S; Yahiro Y; Sakuma D; Matsuyama K; Imamura K; Kawamura I; Setoguchi T; Ishidou Y; Nagano S; Komiya S
Sci Rep; 2017 Oct; 7(1):13494. PubMed ID: 29044189
[TBL] [Abstract][Full Text] [Related]
36. Molecular profiling of human chondrosarcomas for matrix production and cancer markers.
Söderström M; Böhling T; Ekfors T; Nelimarkka L; Aro HT; Vuorio E
Int J Cancer; 2002 Jul; 100(2):144-51. PubMed ID: 12115562
[TBL] [Abstract][Full Text] [Related]
37. Utility of planar bone scintigraphy to distinguish benign osteochondromas from malignant chondrosarcomas.
Hendel HW; Daugaard S; Kjaer A
Clin Nucl Med; 2002 Sep; 27(9):622-4. PubMed ID: 12192277
[TBL] [Abstract][Full Text] [Related]
38. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells.
Weiss S; Hennig T; Bock R; Steck E; Richter W
J Cell Physiol; 2010 Apr; 223(1):84-93. PubMed ID: 20049852
[TBL] [Abstract][Full Text] [Related]
39. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
40. Heat shock protein 72 expression in chondrosarcoma correlates with differentiation.
Trieb K; Kohlbeck R; Lang S; Klinger H; Blahovec H; Kotz R
J Cancer Res Clin Oncol; 2000 Nov; 126(11):667-70. PubMed ID: 11079732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
